Skip to content

Study · Animal study (in vivo) · caenorhabditis elegans · 2026

1 result

Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.

Schaak A, Walker M, Worden B, Foksinska A, Ray R, Stottmann R, Cole FS, Walsh JR, Marcette JD

Epilepsy research28 Mar 2026

PMID41955672 (opens in a new tab)DOI10.1016/j.eplepsyres.2026.107782 (opens in a new tab)PepBankPUB-41955672
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

Recessive, loss of function, genomic variants in CAMSAP1 and 2 (calmodulin-regulated spectrin-associated proteins 1 and 2) cause a neurodevelopmental seizure disorder in humans that currently lacks specific treatments. CAMSAP proteins stabilize dynamics of the minus-ends of microtubules and regulate regenerative signaling cascades. We explored microtubule-stabilizing drugs as potential therapeutic interventions using a convulsion assay in the model organism Caenorhabditis elegans. We found that animals with genetically disrupted ptrn-1 (the C. elegans homolog of CAMSAP1) exhibited elevated convulsion frequency relative to wild type, and that Epothilone B and Valproic Acid reduced convulsions. We also found that Paclitaxel increased convulsions, and Davunetide produced variable outcomes. These results suggest that pharmacologic microtubule stabilization is a promising strategy for diseases caused by genetic disruption to CAMSAP function.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In a Caenorhabditis elegans model of CAMSAP disorders, davunetide produced variable convulsion outcomes.

    In plain wordsIn worms with a CAMSAP disorder model, davunetide had variable effects on convulsions.

    Peptide
    Davunetide
    Outcome
    MixedConvulsions
    Study

    Caenorhabditis elegansn: not reported in source

    ptrn-1 disruption
    Outcome group
    Seizures · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Davunetide produced variable outcomes.
    1 context sentence
    Summary · context
    We explored microtubule-stabilizing drugs as potential therapeutic interventions using a convulsion assay in the model organism Caenorhabditis elegans.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.